Radiochemical synthesis of [I-123]2-iodo-lisuride for dopamine D2-receptor studies

被引:4
作者
Bier, D [1 ]
Dutschka, K [1 ]
Knust, EJ [1 ]
机构
[1] UNIV ESSEN GESAMTHSCH KLINIKUM,NUKL CHEM & RADIOPHARM KLIN NUKL MED,D-45122 ESSEN,GERMANY
来源
NUCLEAR MEDICINE AND BIOLOGY | 1996年 / 23卷 / 03期
关键词
D O I
10.1016/0969-8051(96)00018-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
By variation of reaction parameters iodination of 3-(9,10-didehydro-6-methyl-8 alpha-ergolinyl)-1,1-diethylurea (lisuride) was performed with the radiohalogen [I-123]iodine (t(1/2) = 13.3 h). For comparative experiments and stability studies the beta(-)emitting radioisotope [I-131]iodine (t(1/2) = 8.04 d) was also used. Reaction occurs at the activated position 2 of the molecule, thus leading to [I-123]3-(9,10-didehydro-2-iodo-6-methyl-8 alpha-ergolinyl)-1, 1-diethylurea ([I-123]2-iodo-lisuride, [I-123]ILIS) Or the analogous [I-131]iodine-labeled compound, respectively. Electrophilic radioactive species were generated by oxidation of no-carrier-added (n.c.a.) iodide with IODOGEN (1,3,4,6-tett-achloro-3 alpha,6 alpha-diphenylglycouril) fixed on the glass wall of the reaction vial prior to iodination, After optimization of reaction parameters [I-123]2-iodo-lisuride after HPLC-purification was obtained with radiochemical yields of 70 +/- 5% and a radiochemical purity of >97%. In n.c.a. syntheses, specific activities of the product were in the range between 4440 and 7400 GBq/mu mol (120-200 Ci/mu mol) corresponding to 50-85% of the theoretical value.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 14 条
[1]  
BUCHALI K, 1991, NUKLEARMED, V30, P137
[2]  
CHABRIAT H, 1992, J NUCL MED, V33, P1481
[3]   DIRECT DOPAMINERGIC ACTION OF LISURIDE HYDROGEN MALEATE, AN ERGOT DERIVATIVE, IN MICE [J].
HOROWSKI, R ;
WACHTEL, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1976, 36 (02) :373-383
[4]  
HOROWSKI R, 1989, MORBUS PARKINSON NEU, P43
[5]  
KUNG HF, 1990, J NUCL MED, V31, P573
[6]  
LOC'H C, 1989, European Journal of Nuclear Medicine, V15, P403
[7]  
LOC'H C, 1989, Journal of Labelled Compounds and Radiopharmaceuticals, V26, P100
[8]  
LOC'H C, 1991, Journal of Labelled Compounds and Radiopharmaceuticals, V30, P377
[9]   [BR-76] BROMOLISURIDE - A NEW TOOL FOR QUANTITATIVE INVIVO IMAGING OF D-2 DOPAMINE-RECEPTORS [J].
MAZIERE, B ;
LOCH, C ;
STULZAFT, O ;
HANTRAYE, P ;
OTTAVIANI, M ;
COMAR, D ;
MAZIERE, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 127 (03) :239-247
[10]  
MAZIERE B, 1989, Journal of Nuclear Medicine, V30, P731